Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Actinogen Medical ( (AU:ACW) ) has shared an update.
Actinogen Medical announced successful trial results for their Xanamem tablet formulation, confirming consistent therapeutic blood levels in both fed and fasted states. This supports the use of a 10 mg daily dose in ongoing trials for Alzheimer’s disease, highlighting Xanamem’s potential as a flexible and effective treatment option. The trial’s outcomes reinforce Actinogen’s position in the industry as a developer of innovative therapies for neurological conditions, potentially impacting stakeholders by advancing treatment options for Alzheimer’s and related diseases.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease and Depression, with future studies planned for Fragile X Syndrome and other conditions. The company aims to address the substantial unmet medical need for improved treatments for cognitive dysfunction and neuropsychological burdens associated with these diseases.
Average Trading Volume: 3,778,263
Technical Sentiment Signal: Hold
Current Market Cap: A$95.31M
Learn more about ACW stock on TipRanks’ Stock Analysis page.